In this article, we will discuss 5 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. If you want to read our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, go directly to 15 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital.
5. Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX)
Akkaraju and Dybbs’ Stake Value: $38,966,000
Percentage of Srini Akkaraju and Michael Dybbs’ 13F Portfolio: 4.81%
Number of Hedge Fund Holders: 13
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) is a clinical-stage biopharmaceutical business that develops and commercializes new therapeutics to treat rare hematologic disorders and malignancies. It was incorporated in 2007, and it stands fifth on the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) currently has a $1.14 billion market capitalization.
On August 17, H.C. Wainwright analyst Robert Burns lowered the price target on Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) to $53 from $55 and kept a “Buy” rating on the shares after the second-quarter results. On August 13, Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) declared earnings for the second quarter of 2021. It posted earnings per share of -$0.92, missing the estimates by $0.13.
The hedge fund chaired by Srini Akkaraju and Michael Dybbs owns 1.57 million shares in Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) worth over $38.97 million, representing 4.81% of their investment portfolio. Peter Kolchinsky’s RA Capital Management is the most significant stakeholder in Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) out of the 873 hedge funds tracked by Insider Monkey as of the second quarter of 2021. The hedge fund owns 9.01 million shares of the company, worth $224.30 million.
4. Instil Bio, Inc. (NASDAQ:TIL)
Akkaraju and Dybbs’ Stake Value: $41,449,000
Percentage of Srini Akkaraju and Michael Dybbs’ 13F Portfolio: 5.11%
Number of Hedge Fund Holders: 14
Instil Bio, Inc. (NASDAQ:TIL) is a clinical-stage biopharmaceutical firm that develops treatments for cancer patients. The company was founded in 2018 and is placed fourth on the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Instil Bio, Inc. (NASDAQ:TIL) shares have returned 6.48% to investors during the course of the past 12 months.
On August 12, Instil Bio, Inc. (NASDAQ:TIL) announced earnings for the second quarter of 2021. It reported earnings per share of –$0.27, missing the consensus by $0.06. Baird analyst Jack Allen initiated coverage of Instil Bio, Inc. (NASDAQ:TIL) with an “Outperform” rating and gave a price target of $34.
The hedge fund managed by Srini Akkaraju and Michael Dybbs currently holds 2.15 million shares of Instil Bio, Inc. (NASDAQ:TIL) that amount to $41.45 million after increasing its stakes by 39% in the second quarter of 2021. Instil Bio, Inc. (NASDAQ:TIL) occupies 5.11% of Samsara BioCapital’s total portfolio. In addition, Albert Cha and Frank Kung’s Vivo Capital is a leading shareholder in Adobe Inc. (NASDAQ: ADBE), with 12.49 million shares worth $241.25 million.
3. Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Akkaraju and Dybbs’ Stake Value: $44,738,000
Percentage of Srini Akkaraju and Michael Dybbs’ 13F Portfolio: 5.52%
Number of Hedge Fund Holders: 14
Chinook Therapeutics, Inc. (NASDAQ:KDNY) is a clinical-stage biotechnology firm specializing in the research, development, and commercialization of kidney disease precision therapies. The company was established in 2018 and stands third on the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Chinook Therapeutics, Inc. (NASDAQ:KDNY) presently has a market capitalization of $570.3 million.
On August 12, Chinook Therapeutics, Inc. (NASDAQ:KDNY) announced earnings for the second quarter of 2021. It posted earnings per share of -$0.97, missing the estimates by $0.19. In addition, revenue over the period was $0.03 million, missing the estimates by $0.01 million.
The hedge fund chaired by Srini Akkaraju and Michael Dybbs currently owns 3.17 million shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY) worth over $44.74 million. Chinook Therapeutics, Inc. (NASDAQ:KDNY) occupies 5.52% of Samsara BioCapital’s overall equity. In addition, hedge funds are loading up on Chinook Therapeutics, Inc. (NASDAQ:KDNY), as Insider Monkey’s data shows that 19 hedge funds held stakes in the company in the second quarter of 2021, compared to 15 funds in the first quarter of 2021.
2. Nkarta, Inc. (NASDAQ:NKTX)
Akkaraju and Dybbs’ Stake Value: $64,480,000
Percentage of Srini Akkaraju and Michael Dybbs’ 13F Portfolio: 7.95%
Number of Hedge Fund Holders: 14
Nkarta, Inc. (NASDAQ:NKTX) develops and sells cell therapies for cancer treatment. The company was incorporated in 2015 and is ranked second on the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Nkarta, Inc. (NASDAQ:NKTX) currently has a market capitalization of $896.37 million.
On August 12, Nkarta, Inc. (NASDAQ:NKTX) posted earnings for the second quarter of 2021. It declared earnings per share of -$0.66, missing the analysts’ expectations by $0.02. On July 15, Oppenheimer analyst Matthew Biegler initiated coverage of Nkarta, Inc. (NASDAQ:NKTX) with an “Outperform” rating and gave a price target of $75.
Srini Akkaraju and Michael Dybbs’ Samsara BioCapital owns $64.48 million stake in Nkarta, Inc. (NASDAQ:NKTX). RA Capital Management is Nkarta, Inc.’s (NASDAQ:NKTX) most significant stakeholder, with 5.61 million shares worth $177.63 million.
1. Graphite Bio, Inc. (NASDAQ:GRPH)
Akkaraju and Dybbs’ Stake Value: $228,374,000
Percentage of Srini Akkaraju and Michael Dybbs’ 13F Portfolio: 28.19%
Number of Hedge Fund Holders: 22
Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage gene-editing firm, is developing treatments for severe and life-threatening illnesses. The company was founded in 2017 and is placed first on the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital.
On August 12, Graphite Bio, Inc. (NASDAQ:GRPH) announced earnings for the second quarter of 2021. It reported earnings per share of -$3.45, missing the estimates by $2.35. On July 20, Morgan Stanley analyst Jeffrey Hung initiated coverage of Graphite Bio, Inc. (NASDAQ:GRPH) with an “Overweight” rating and gave a price target of $35.
Samsara BioCapital holds 7.43 million shares in Graphite Bio, Inc. (NASDAQdybbs:GRPH) worth over $228.37 million, representing 28.19% of their portfolio. The stock is a new arrival on Srini Akkaraju and Michael Dybbs’ portfolio. Insider Monkey’s data shows that 22 elite hedge funds held stakes in Graphite Bio, Inc. (NASDAQ:GRPH) in the second quarter.
You can also take a peek at 10 Best Biotech Stocks to Buy According to Cathie Wood and 11 Best Pharma and Biotech Stocks to Buy
